Safety and effectiveness of secukinumab in skin and joint conditions in Korea
Observes secukinumab use in people with hidradenitis suppurativa, childhood psoriasis, or juvenile arthritis.
Plain-language title generated from the registry record
Registry title: Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 100 years old?
Source: NCT07243782, who can take part
Where in South Korea
- SeoulSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07243782
- Record updated
- 5 March 2026
- Original description
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in KoreaRead full original descriptionShow less
Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
Inclusion: Hidradenitis suppurativa:; Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication; Patients who have agreed to participate in study (written informed consent); Pediatric plaque psoriasis:; Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication; Patients with patient or guardian consent to participate in study (written informed consent); Juvenile idiopathic arthritis:; Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication; Patients with patient or guardian consent to participate in study (written informed consent).
Exclusion: Patients who are contraindicated according to national prescribing information; Patients participating in other interventional clinical trials.